Hypermarcas (OTCMKTS:HYPMY) Shares Down 4.9% – Here’s What Happened

Hypermarcas (OTCMKTS:HYPMY) dropped 4.9% during trading on Friday . The stock traded as low as $4.61 and last traded at $4.61. Approximately 8,543 shares traded hands during trading, a decline of 84% from the average daily volume of 54,724 shares. The stock had previously closed at $4.85.

Hypermarcas Stock Performance

The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of 20.04 and a beta of 0.82. The business has a 50-day moving average price of $4.36 and a 200-day moving average price of $4.46.

Hypermarcas (OTCMKTS:HYPMY) last released its earnings results on Wednesday, November 12th. The company reported $0.13 EPS for the quarter. Hypermarcas had a net margin of 12.03% and a return on equity of 6.99%. The company had revenue of $408.83 million during the quarter.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.